Explore more publications!

Health Update Bahamas: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Update Bahamas.

Press releases published on November 19, 2025

Profusa Announces Third Quarter Business and Financial Highlights
Apollomics Announces Settlement of Cayman Litigation
FDA Pilots Faster Clarifications to Meeting Minutes
Heartflow to Participate in the Piper Sandler 37th Annual Healthcare Conference
Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results
EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications
Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference
SynCardia Completes First In Vivo Implantations of Next-Generation Emperor Total Artificial Heart
Meihua International Announces 1-For-100 Reverse Share Split
Carlsmed, Inc. To Participate in the Piper Sandler 37th Annual Healthcare Conference
Vista Physical Therapy Expands North Texas Footprint With Two New Outpatient Clinics in Rockwall and Frisco
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”
New Report Introduces First Legal Blueprint for Climate-Resilient Water and Sanitation in the U.S.
ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
The American Society of Pain and Neuroscience (ASPN) Issues Consensus Guidelines on Peripheral Nerve Stimulation
Spherix Global Insights Reports Rapidly Evolving U.S. PNH Market as Ultomiris Prescriptions Reach Parity with Iron Supplements
Protext Mobility, Inc. (OTC: TXTM) Provides Shareholder Update
Gene Therapy for Ocular Rare Disease Market to Exhibit Phenomenal Growth During the Forecast Period (2025–2034) Due to Expanding Pipeline and Clinical Trial Activities | DelveInsight
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions